leuprolide acetate for depot suspension

P2, N=74, Completed, National Institute of Mental Health (NIMH) | N=54 --> 74

We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy...As second-line therapy, he received gemcitabine and docetaxel...Alternative regimens include temozolomide plus irinotecan or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.

P2, N=25, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Nov 2028 | Trial primary completion date: Jan 2027 --> Nov 2028

P2, N=140, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting

P2, N=88, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting

P3, N=504, Completed, Alliance Foundation Trials, LLC. | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jun 2025

P2, N=75, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

Postoperatively, a surgery combined with targeted and immunotherapy regimen was initiated: leuprorelin + rezvilutamide for the acinar adenocarcinoma and disitamab vedotin + toripalimab for the urothelial carcinoma. The protocol of surgery combined with targeted and immunotherapy offers a new treatment strategy for this rare malignancy. This study provides valuable insights for clinical diagnosis and management.

Following initial surgery and adjuvant treatment with four cycles each of fluorouracil, doxorubicin, and Cyclophosphamide chemotherapy and paclitaxel, radiotherapy and tamoxifen, the patient developed multiple metastases to the liver, lung and bones 3 years later...The patient maintained a PR and was managed with maintenance leuprolide, letrozole and palbociclib. The patient developed disease progression and died in July 2024, leading to a progression-free survival of ~ two years and an overall survival of two years and six months. To the best of our knowledge, the present case is among the first to report the safety and efficacy of 12 cycles of NDLS in MBC.

P3, N=1538, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed

P3, N=239, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2029 --> Sep 2025

P4, N=10, Completed, University of Colorado, Denver | Recruiting --> Completed | N=228 --> 10 | Trial completion date: Mar 2028 --> Jul 2025 | Trial primary completion date: Mar 2028 --> Jul 2025